Nonprofit buys experimental cancer drug to maintain patient access - Takeaways - MDSpire

Nonprofit buys experimental cancer drug to maintain patient access

Share

1

Blood Cancer United acquired the remaining supplies of Luvelta, a discontinued investigational cancer drug, to ensure patient access.
2

The organization will manage a compassionate-use program for children with a rare blood cancer, distributing Luvelta at no cost.
3

Luvelta targets the folate receptor and can aid in stem cell transplantation for certain acute myeloid leukemia patients.
4

Blood Cancer United aims to create clearer regulatory paths for pediatric drug development, addressing economic challenges faced by drugmakers.
5

The organization anticipates enough Luvelta supplies for several years, with plans for stability testing to potentially extend shelf life.